A detailed history of Kennedy Capital Management, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Kennedy Capital Management, Inc. holds 23,615 shares of VRTX stock, worth $11.4 Million. This represents 0.23% of its overall portfolio holdings.

Number of Shares
23,615
Previous 13,531 74.53%
Holding current value
$11.4 Million
Previous $6.29 Million 51.13%
% of portfolio
0.23%
Previous 0.15%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 13, 2025

BUY
$396.64 - $516.74 $4 Million - $5.21 Million
10,084 Added 74.53%
23,615 $9.51 Million
Q3 2024

Nov 14, 2024

BUY
$460.0 - $505.78 $708,400 - $778,901
1,540 Added 12.84%
13,531 $6.29 Million
Q2 2024

Aug 14, 2024

BUY
$392.81 - $485.53 $1.45 Million - $1.79 Million
3,680 Added 44.28%
11,991 $5.62 Million
Q1 2024

May 15, 2024

BUY
$407.69 - $446.08 $3.39 Million - $3.71 Million
8,311 New
8,311 $3.47 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $124B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Kennedy Capital Management, Inc. Portfolio

Follow Kennedy Capital Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kennedy Capital Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Kennedy Capital Management, Inc. with notifications on news.